The Immunitary role in chronic prostatitis and growth factors as promoter of BPH
Open Access
- 1 January 2017
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 2 (1), 001-013
- https://doi.org/10.29328/journal.icci.1001003
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH)?BJU International, 2013
- Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - DutasterideJournal of Clinical Pharmacy & Therapeutics, 2013
- Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE studyBMJ, 2013
- Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP‐1/CCL2 and VCAM‐1, in vitroBJU International, 2012
- Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase InhibitorKorean Journal of Andrology, 2012
- Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile (Review)Molecular Medicine Reports, 2011
- Introduction of trifluoromethyl group into diphenyl diselenide molecule alters its toxicity and protective effect against damage induced by 2-nitropropane in ratsExperimental and Toxicologic Pathology, 2009
- Finasteride to Evaluate the Efficacy of Dutasteride in the Management of Patients with Lower Urinary Tract Symptoms and Enlarged ProstateArchives of Andrology, 2007
- BPH and Inflammation: Pharmacological Effects of Permixon on Histological and Molecular Inflammatory Markers. Results of a Double Blind Pilot Clinical AssayEuropean Urology, 2003
- Inhibition of nuclear factor kappa B and induction of apoptosis in T‐lymphocytes by sulfasalazineBritish Journal of Pharmacology, 1999